Abstract
Objective: Osteopontin (OPN), a phosphorylated sialoprotein, has been shown to overexpress in a variety of cancers and to contribute tumor progression and metastasis by increasing cell migration and adhesion. In the current study, we aimed to investigate the prognostic and predictive role of OPN in patients with advanced gastric cancer.
Methods: A total of 42 consecutive chemonaive patients with advanced gastric cancer and 29 healthy controls were included. The patients were treated with a modified DCF regimen. The blood samples were obtained before each chemotherapy cycle from the patients and once from the healthy controls. The plasma OPN is measured by ELISA.
Results: The overall response and disease stabilization rates were 25% and 72%, respectively. The median serum OPN level of the patient group was significantly higher compared to healthy controls (176.9 ng/ml (range: 41.5 -521.4) vs 64.3 ng/ml (range 42.1-105.3 ng/ml), p<0.0001). The median overall survival time was 7.0 ± 1.1 (95% CI: 4.9–9.2) months and 1-year overall survival rate was 20.8%. The patients who responded to mDCF had lower plasma OPN levels than the non-responding ones (110.7±29.3 ng/mL, 211.9±24.4 ng/mL respectively, p=0.002). The performance status and the plasma OPN levels were found to be significant factors for overall survival in the multivariate analysis (p=0.004 and 0.016, respectively).
Conclusion: The serum OPN seems to be a novel significant prognostic and predictive factor in patients with advanced gastric cancer who were treated with DCF regimen.
Keywords: Gastric cancer, predictive factor, prognostic factor, Osteopontin, biomarker, oncologist.
Combinatorial Chemistry & High Throughput Screening
Title:Osteopontin is a Prognostic Factor in Patients with Advanced Gastric Cancer
Volume: 24 Issue: 8
Author(s): Ozan Yazici*, Mutlu Dogan, Guze Ozal, Sedef Hande Aktas, Ahmet Demirkazik, Gungor Utkan, Filiz Cay Senler, Fikri Icli and Hakan Akbulut
Affiliation:
- Department of Medical Oncology, Gazi University School of Medicine, Besevler/Ankara,Turkey
Keywords: Gastric cancer, predictive factor, prognostic factor, Osteopontin, biomarker, oncologist.
Abstract:
Objective: Osteopontin (OPN), a phosphorylated sialoprotein, has been shown to overexpress in a variety of cancers and to contribute tumor progression and metastasis by increasing cell migration and adhesion. In the current study, we aimed to investigate the prognostic and predictive role of OPN in patients with advanced gastric cancer.
Methods: A total of 42 consecutive chemonaive patients with advanced gastric cancer and 29 healthy controls were included. The patients were treated with a modified DCF regimen. The blood samples were obtained before each chemotherapy cycle from the patients and once from the healthy controls. The plasma OPN is measured by ELISA.
Results: The overall response and disease stabilization rates were 25% and 72%, respectively. The median serum OPN level of the patient group was significantly higher compared to healthy controls (176.9 ng/ml (range: 41.5 -521.4) vs 64.3 ng/ml (range 42.1-105.3 ng/ml), p<0.0001). The median overall survival time was 7.0 ± 1.1 (95% CI: 4.9–9.2) months and 1-year overall survival rate was 20.8%. The patients who responded to mDCF had lower plasma OPN levels than the non-responding ones (110.7±29.3 ng/mL, 211.9±24.4 ng/mL respectively, p=0.002). The performance status and the plasma OPN levels were found to be significant factors for overall survival in the multivariate analysis (p=0.004 and 0.016, respectively).
Conclusion: The serum OPN seems to be a novel significant prognostic and predictive factor in patients with advanced gastric cancer who were treated with DCF regimen.
Export Options
About this article
Cite this article as:
Yazici Ozan*, Dogan Mutlu, Ozal Guze, Aktas Hande Sedef , Demirkazik Ahmet, Utkan Gungor, Senler Cay Filiz , Icli Fikri and Akbulut Hakan, Osteopontin is a Prognostic Factor in Patients with Advanced Gastric Cancer, Combinatorial Chemistry & High Throughput Screening 2021; 24 (8) . https://dx.doi.org/10.2174/1386207323666200902135349
DOI https://dx.doi.org/10.2174/1386207323666200902135349 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
Call for Papers in Thematic Issues
Artificial Intelligence Methods for Biomedical, Biochemical and Bioinformatics Problems
Recently, a large number of technologies based on artificial intelligence have been developed and applied to solve a diverse range of problems in the areas of biomedical, biochemical and bioinformatics problems. By utilizing powerful computing resources and massive amounts of data, methods based on artificial intelligence can significantly improve the ...read more
Eco-friendly Agents for Biological Control of Pathogenic Diseases
The discovery of an alternative biological approach to disease management includes work on medicinal products derived from natural sources as a starting point for the development of eco-friendly agents for these diseases and the injuries they cause, as well as reducing human contact with hazardous chemicals and their residues. We ...read more
Emerging trends in diseases mechanisms, noble drug targets and therapeutic strategies: focus on immunological and inflammatory disorders
Recently infectious and inflammatory diseases have been a key concern worldwide due to tremendous morbidity and mortality world Wide. Recent, nCOVID-9 pandemic is a good example for the emerging infectious disease outbreak. The world is facing many emerging and re-emerging diseases out breaks at present however, there is huge lack ...read more
Exploring Spectral Graph Theory in Combinatorial Chemistry
Scope of the Thematic Issue: Combinatorial chemistry involves the synthesis and analysis of a large number of diverse compounds simultaneously. Traditional methods rely on brute force experimentation, which can be time-consuming and resource-intensive. Spectral Graph Theory, a branch of mathematics dealing with the properties of graphs in relation to the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology Cyclodextrin-Based Delivery Systems for Arthritic Diseases: From Development to Experimental Therapeutics
Current Pharmaceutical Design Lipid Rafts, Endoplasmic Reticulum and Mitochondria in the Antitumor Action of the Alkylphospholipid Analog Edelfosine
Anti-Cancer Agents in Medicinal Chemistry Nanomedicine to Overcome Cancer Multidrug Resistance
Current Drug Metabolism Effect of Intestinal Flora Clearance on Liver Proteomics in Mice
Current Proteomics The Early Bird Catches the Worm – Can Evolution Teach us Lessons in Fighting HIV?
Current HIV Research The Vanilloid Agonist Resiniferatoxin for Interventional-Based Pain Control
Current Topics in Medicinal Chemistry The Re-Emergence of Aerosol Gene Delivery: A Viable Approach to Lung Cancer Therapy
Current Cancer Drug Targets Mycotherapy of Cancer: An Update on Cytotoxic and Antitumor Activities of Mushrooms, Bioactive Principles and Molecular Mechanisms of their Action
Current Topics in Medicinal Chemistry Molecular Mechanisms Regulating Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Genome and Transcriptome Analysis of Neuroblastoma Advanced Diagnosis from Innovative Therapies
Current Pharmaceutical Design Natural Products as Anticancer Agents
Current Drug Targets Recent Progress on Apoptotic Activity of Triazoles
Current Drug Targets The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Editorial
Recent Patents on Anti-Cancer Drug Discovery Marine Peptides and Related Compounds in Clinical Trial+
Anti-Cancer Agents in Medicinal Chemistry Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
Current Cancer Drug Targets CD248: Reviewing its Role in Health and Disease
Current Drug Targets NF-κB Decoy Oligodeoxynucleotides Inhibits Kupffer Cell Activation
Current Signal Transduction Therapy DNAM-1 (CD226): A Two-Sword Fencer for Innate and Adaptive Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents